Gleevec (Imatinib): The Targeted Therapy for Leukemia and Other Cancers
What is Gleevec (Imatinib)?
Gleevec, also known as Imatinib, is a targeted therapy drug used to treat certain types of cancers, including chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
How Gleevec Works
Imatinib targets and inhibits the BCR-ABL fusion protein, which is present in certain cancer cells, blocking the signals that promote their growth.
When to Use Gleevec
● Chronic Myelogenous Leukemia (CML): Treats CML by blocking the BCR-ABL fusion protein.
● Gastrointestinal Stromal Tumors (GIST): Treats certain rare forms of cancer in the stomach or intestines.
Dosage
● Adult Dose: 400 mg daily, typically taken with food it can be increased to 600 mg if tolerated and in cases of blast crisis. If still there is progression of the disease and lack of response after 6 -12 months it can be increased to a maximum of 800 mg daily.
● Pediatric Dose: 340 mg/m²/day once a day or in two divided doses for children with CML.
Side Effects
● Nausea, fatigue, fluid retention, rash, and liver problems.
Common Brands in India: Gleevec, Imatinib.
FAQ
How does Gleevec work for cancer?
It blocks the growth signals in cancer cells by inhibiting the BCR-ABL fusion protein.
Can Gleevec be used for other cancers?
Yes, it is also used for other cancers like Ph+ acute lymphoblastic leukemia (ALL).
Is Gleevec safe during pregnancy?
It is generally not recommended during pregnancy unless absolutely necessary.
Disclaimer
Gleevec should be prescribed and monitored by a healthcare provider. HealthPil connects you with oncologists for targeted cancer therapy.
